TP53-Mutated AML and Treatment Outcomes in the Era of Hypomethylating Agent/Venetoclax Therapy

D. Mueller MD
S. Santhosh
A. Singhal MD
D. W. Chitty DO
D. E. Gladstone MD
B. Goldberg MD
E. Jou MD
J. E. Kolitz MD

This paper has been withdrawn.
 
Jun 3rd, 11:30 AM

TP53-Mutated AML and Treatment Outcomes in the Era of Hypomethylating Agent/Venetoclax Therapy